{
    "organizations": [],
    "uuid": "63623f423c8c164d1266b63b4f0876bcf518bab5",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-puma-biotechnology-and-pint-pharma/brief-puma-biotechnology-and-pint-pharma-enter-licensing-agreement-to-commercialize-nerlynx-in-latin-america-idUSFWN1RG0P5",
    "ord_in_thread": 0,
    "title": "BRIEF-Puma Biotechnology And Pint Pharma Enter Licensing Agreement To Commercialize Nerlynx In Latin America",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 3 (Reuters) - Puma Biotechnology Inc:\n* PUMA BIOTECHNOLOGY AND PINT PHARMA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN LATIN AMERICA\n* ‍PUMA WILL RECEIVE AN UPFRONT PAYMENT AS WELL AS POTENTIAL REGULATORY AND COMMERCIAL MILESTONE PAYMENTS TOTALING UP TO $34.5 MILLION​\n* DIGIT ROYALTIES ON NERLYNX SALES IN LATIN AMERICA * DEAL FOR PINT PHARMA TO COMMERCIALIZE NERLYNX IN ARGENTINA, BRAZIL, CHILE, COLOMBIA, MEXICO AND REST OF LATIN AMERICA​\n* PINT PHARMA WILL BE RESPONSIBLE FOR COMMERCIALIZING NERLYNX IN LATIN AMERICA Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-03T20:48:00.000+03:00",
    "crawled": "2018-04-03T15:54:46.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "puma",
        "biotechnology",
        "inc",
        "puma",
        "biotechnology",
        "pint",
        "pharma",
        "enter",
        "exclusive",
        "licensing",
        "agreement",
        "commercialize",
        "neratinib",
        "latin",
        "america",
        "receive",
        "upfront",
        "payment",
        "well",
        "potential",
        "regulatory",
        "commercial",
        "milestone",
        "payment",
        "totaling",
        "digit",
        "royalty",
        "nerlynx",
        "sale",
        "latin",
        "america",
        "deal",
        "pint",
        "pharma",
        "commercialize",
        "nerlynx",
        "argentina",
        "brazil",
        "chile",
        "colombia",
        "mexico",
        "rest",
        "latin",
        "pint",
        "pharma",
        "responsible",
        "commercializing",
        "nerlynx",
        "latin",
        "america",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}